Abstract:INTRODUCTION As aggregation underpins Tau toxicity, aggregation inhibitor peptides may have disease‐modifying potential. They are therefore currently being designed and target either the 306VQIVYK311 aggregation‐promoting hotspot found in all Tau isoforms or the 275VQIINK280 aggregation‐promoting hotspot found in 4R isoforms. However, for any Tau aggregation inhibitor to potentially be clinically relevant for other tauopathies, it should target both hotspots to suppress aggregation of Tau isoforms, be stable, cross the blood‐brain barrier, and rescue aggregation‐dependent Tau phenotypes in vivo. METHODS We developed a retro‐inverso, stable D‐amino peptide, RI‐AG03 [Ac‐rrrrrrrrGpkyk(ac)iqvGr‐NH2], based on the 306VQIVYK311 hotspots which exhibit these disease‐relevant attributes. RESULTS Unlike other aggregation inhibitors, RI‐AG03 effectively suppresses aggregation of multiple Tau species containing both hotspots in vitro and in vivo, is non‐toxic, and suppresses aggregation‐dependent neurodegenerative and behavioral phenotypes. DISCUSSION RI‐AG03 therefore meets many clinically relevant requirements for an anti‐aggregation Tau therapeutic and should be explored further for its disease‐modifying potential for Tauopathies. Highlights Our manuscript describes the development of a novel peptide inhibitor of Tau aggregation, a retro‐inverso, stable D‐amino peptide called RI‐AG03 that displays many clinically relevant attributes. We show its efficacy in preventing Tau aggregation in both in vitro and in vivo experimental models while being non‐toxic to cells. RI‐AG03 also rescues a biosensor cell line that stably expresses Tau repeat domains with the P301S mutation fused to Cer/Clo and rescues aggregation‐dependent phenotypes in vivo, suppressing neurodegeneration and extending lifespan. Collectively our data describe several properties and attributes of RI‐AG03 that make it a promising disease‐modifying candidate to explore for reducing pathogenic Tau aggregation in Tauopathies such as Alzheimer's disease. Given the real interest in reducing Tau aggregation and the potential clinical benefit of using such agents in clinical practice, RI‐AG03 should be investigated further for the treatment of Tauopathies after validation in mammalian models. Tau aggregation inhibitors are the obvious first choice as Tau‐based therapies as much of Tau‐mediated toxicity is aggregation dependent. Indeed, there are many research efforts focusing on this therapeutic strategy with aggregation inhibitors being designed against one of the two aggregation‐promoting hotspots of the Tau protein. To our knowledge, RI‐AG03 is the only peptide aggregation inhibitor that inhibits aggregation of Tau by targeting both aggregation‐promoting hotspot motifs simultaneously. As such, we believe that our study will have a significant impact on drug discovery efforts in this arena.

A Single-Chain Variable Fragment Antibody Inhibits Aggregation of Phosphorylated Tau and Ameliorates Tau Toxicity <i>in vitro</i> and <i>in vivo</i>

Novel Cathepsin D Inhibitors Block the Formation of Hyperphosphorylated Tau Fragments in Hippocampus

Single chain variable fragment against aβ expressed in baculovirus inhibits abeta fibril elongation and promotes its disaggregation.

A Tauopathy-Homing and Autophagy-Activating Nanoassembly for Specific Clearance of Pathogenic Tau in Alzheimer's Disease.

Conformation-dependent single-chain variable fragment antibodies specifically recognize beta-amyloid oligomers.

Single Chain Fv Antibodies against the 25−35 Aβ Fragment Inhibit Aggregation and Toxicity of Aβ42

Single chain Fv antibodies against the 25-35 Abeta fragment inhibit aggregation and toxicity of Abeta42.

Tau-Targeted Multifunctional Nanoinhibitor for Alzheimer's Disease.

Conformation-selective tau monoclonal antibodies inhibit tau pathology in primary neurons and a mouse model of Alzheimer’s disease

Artificial intelligence assisted identification of potential tau aggregation inhibitors: ligand- and structure-based virtual screening, in silico ADME, and molecular dynamics study

IDENTIFICATION OF A SMALL MOLECULE INHIBITOR OF TAU AGGREGATION

A novel D-amino acid peptide with therapeutic potential (ISAD1) inhibits aggregation of neurotoxic disease-relevant mutant Tau and prevents Tau toxicity in vitro

A novel peptide‐based tau aggregation inhibitor as a potential therapeutic for Alzheimer's disease and other tauopathies

Selective Degradation of Hyperphosphorylated Tau by Proteolysis-Targeting Chimeras Ameliorates Cognitive Function in Alzheimer’s Disease Model Mice

Development of a pan‐tau multivalent nanobody that binds tau aggregation motifs and recognizes pathological tau aggregates

Anti-tau conformational scFv MC1 antibody efficiently reduces pathological tau species in adult JNPL3 mice

Monoclonal antibody Y01 prevents tauopathy progression induced by lysine 280-acetylated tau in cell and mouse models

D-peptide-magnetic nanoparticles fragment tau fibrils and rescue behavioral deficits in a mouse model of Alzheimer's disease

Specific binding of Hsp27 and phosphorylated Tau mitigates abnormal Tau aggregation-induced pathology

Application of engineered antibodies (scFvs and nanobodies) targeting pathological protein aggregates in Alzheimer's disease

Selective degradation of hyperphosphorylated tau by proteolysis-targeting chimeras ameliorates cognitive function in Alzheimer's disease model mice